Keith Speights

Keith Speights


Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries.

Recent articles

3 Stocks to Build Your Portfolio Around

Some stocks you merely buy. Others are at the core of your portfolio. These three belong in the latter category.

Is Amgen a Buy?

The biotech's present and future might not live up to its past.

How Big Is Celgene's Latest Good News?

FDA approval of fedratinib could lead to significantly more revenue for the biotech. But even better news could be on the way.